ReviewFrontiers in bioengineering and biotechnology2025
Advancements in insulin delivery: the potential of natural polymers for improved diabetes management.
Review in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Glucose-Responsive Nanomedicine in Diabetes Therapy: Emerging Advances and Clinical Prospects.Journal of functional biomaterials · 2026Review
- Nanocomposites of Opuntia ficus-indica mucilage-mediated selenium nanoparticles and nanochitosan as antidiabetic candidates in streptozocin-induced diabetic rats.Frontiers in bioengineering and biotechnology · 2026Article
- Emerging nanocarrier systems for the enhanced delivery of active pharmaceutical ingredients to the intestine.Nanomedicine (London, England) · 2025Review
- Natural polymers in diabetes management: formulation prospects ofFrontiers in bioengineering and biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes is a growing global health issue, with millions of people affected by the condition. While insulin therapy is vital for managing both Type 1 and Type 2 diabetes, traditional methods such as subcutaneous injections have notable drawbacks, including pain, discomfort, and difficulty in maintaining stable blood sugar levels. To improve insulin delivery, research is increasingly focused on the use of natural polymers-substances derived from plants, animals, and microorganisms. These polymers, including materials like alginate, chitosan, and hyaluronic acid, have promising properties such as biocompatibility, biodegradability, and the ability to provide controlled, sustained insulin release. By encapsulating insulin in polymers, it is protected from degradation and released in a manner that more closely mirrors the body's natural insulin production. Furthermore, the development of non-invasive delivery methods, such as oral and transdermal systems, is gaining momentum, offering the potential for more patient-friendly treatment options. This review discusses the role of natural polymers in insulin delivery, examining their mechanisms, types, and current research efforts. It also addresses the challenges that remain in advancing these technologies into practical clinical use, aiming to provide more efficient, comfortable, and effective solutions for diabetes management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.